Active Ingredient(s): Safinamide
FDA Approved: * March 21, 2017
Category: Parkinsons

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xadago Overview

Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.[2][3][4] It was approved in Europe in February 2015,[2] in the United States in March 2017,[3] and in Canada in January 2019.[5] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Overd...

Read more Xadago Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Safinamide

Recent Xadago Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Xadago: (3 results)

Sorted by National Drug Code
  • 27505-110 Xadago 50 mg Oral Tablet, Film Coated by Us Worldmeds, LLC
  • 27505-111 Xadago 100 mg Oral Tablet, Film Coated by Us Worldmeds, LLC
  • 68621-0031 Xadago 100 mg Oral Tablet, Film Coated by Catalent Germany Schorndorf Gmbh

Other drugs which contain Safinamide or a similar ingredient: (1 result)